Technetium Tc 99M Depreotide
Technetium Tc 99m depreotide is a somatostatin analog radiolabeled with technetium-99m that binds to somatostatin receptors (subtypes 2, 3, and 5) overexpressed on many neuroendocrine tumors and certain lung cancers. It is used for scintigraphic detection and staging of somatostatin receptor-positive tumors, including pulmonary nodule characterization for malignancy. Its receptor-targeted mechanism enables specific tumor visualization in nuclear medicine imaging.
Peso Molecular
1454,6000 g/mol
TPSA
492,00 Ų
Pharmacokinetics (PK)
Pharmacodynamics (PD)
SMILES
CC(C)[C@H]1C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)CC5=CC=CC=C5)C)CCSCC(=O)NC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N)N.[Tc]
InChI
InChI=1S/C65H96N16O12S2.Tc/c1-38(2)55-64(92)76-49(26-30-95-37-54(83)72-35-44(69)57(85)74-47(20-10-13-28-67)58(86)79-52(36-94)62(90)73-46(56(70)84)19-9-12-27-66)65(93)81(3)53(32-39-15-5-4-6-16-39)63(91)78-50(31-40-22-24-42(82)25-23-40)60(88)77-51(33-41-34-71-45-18-8-7-17-43(41)45)61(89)75-48(59(87)80-55)21-11-14-29-68;/h4-8,15-18,22-25,34,38,44,46-53,55,71,82,94H,9-14,19-21,26-33,35-37,66-69H2,1-3H3,(H2,70,84)(H,72,83)(H,73,90)(H,74,85)(H,75,89)(H,76,92)(H,77,88)(H,78,91)(H,79,86)(H,80,87);/t44-,46-,47-,48-,49-,50-,51+,52-,53-,55-;/m0./s1
Molecular Formula
C65H96N16O12S2Tc
HBD / HBA
17 / 18
Ligações Rotacionáveis
34
Átomos Pesados
96
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Technetium Tc 99m depreotide is a somatostatin analog radiolabeled with technetium-99m that binds to somatostatin receptors (subtypes 2, 3, and 5) overexpressed on many neuroendocrine tumors and certain lung cancers. It is used for scintigraphic detection and staging of somatostatin receptor-positive tumors, including pulmonary nodule characterization for malignancy. Its receptor-targeted mechanism enables specific tumor visualization in nuclear medicine imaging.
Yes, Technetium Tc 99M Depreotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201413. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 72941733. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="technetium-tc-99m-depreotide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/technetium-tc-99m-depreotide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/technetium-tc-99m-depreotide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/technetium-tc-99m-depreotide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="technetium-tc-99m-depreotide"></drugfyi-drug>